Trastuzumab emtansine

Drug Profile

Trastuzumab emtansine

Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Kadcyla; PRO-132365; R3502; RG 3502; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech; ImmunoGen
  • Developer Chugai Pharmaceutical; Genentech; Memorial Sloan-Kettering Cancer Center; Roche
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 23 Mar 2017 Roche plans a phase III trial for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/unresectable) in China (NCT03084939)
  • 18 Jan 2017 Roche terminates a phase III trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease, Monotherapy) in South Korea, Malaysia, Thailand and Taiwan (IV) (NCT02144012)
  • 29 Dec 2016 NICE to discuss comments from HCP, company and public on the 2015 guidance on the funding of trastuzumab emtansine on the NHS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top